Drug intelligence / Profile preview

CBT-201

Development stage: Preclinical
Lead developer: CERES BRAIN Therapeutics
Modality: Recombinant Proteins and Enzymes

Overview

CBT-201 is a preclinical drug initially developed by CERES BRAIN Therapeutics SAS. It is classified as a protein and functions as a reactive oxygen species modulator. The drug was being investigated for nervous system diseases, including tauopathies, but its development for Alzheimer's disease and Parkinson's disease has been discontinued.

Beyond the preview

Go deeper on CBT-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBT-201.

Explore the full profile